Retatrutide (Triple G): The Future of GLP-1 Agonists in Biohacking

The GLP-1 Revolution and Its Limits

The GLP-1 receptor agonist class — semaglutide (Wegovy/Ozempic), tirzepatide (Mounjaro/Zepbound) — represents the most significant advance in obesity pharmacotherapy in decades. Real-world efficacy and the mechanistic understanding of appetite regulation via incretin hormones has shifted both clinical practice and biohacking culture.

But even tirzepatide — currently the most effective approved agent — produces approximately 22% body weight reduction in optimal clinical trial conditions. Many real-world users see 10–15%. The lean mass loss concern (25–35% of weight lost is muscle) remains inadequately addressed.

Retatrutide attempts to solve both problems.

Triple Receptor Agonism: The Mechanism

Retatrutide (LY3437943, Eli Lilly) is engineered to simultaneously activate three incretin receptors:

GLP-1 (glucagon-like peptide-1) receptor: The primary appetite suppression mechanism — reduces hunger via hypothalamic signalling, slows gastric emptying, improves insulin secretion. This is semaglutide's mechanism.

GIP (glucose-dependent insulinotropic polypeptide) receptor: Enhances insulin sensitivity in adipose tissue, synergises with GLP-1 to improve beta-cell function, and — critically — appears to reduce the GI side effects of GLP-1 agonism. This is tirzepatide's addition to GLP-1 alone.

Glucagon receptor: The differentiator. Glucagon activates hepatic fat oxidation, drives thermogenesis (increases energy expenditure), and promotes lipolysis from fat tissue. ^[] Glucagon is paradoxically both catabolic (can break down muscle in excess) and thermogenic — the net effect at the doses used in retatrutide appears to be increased energy expenditure and enhanced fat oxidation without excessive muscle catabolism.

The Phase 2 Data

The NEJM Phase 2 trial enrolled 338 adults with BMI ≥27 across five dose groups and placebo over 48 weeks. ^[]

| Dose | Mean Weight Loss at 48 Weeks | |---|---| | Placebo | 2.1% | | 4 mg/week | 8.7% | | 8 mg/week | 17.1% | | 12 mg/week | 22.8% | | 24 mg/week | 24.2% |

At 24mg/week, 82% of participants achieved ≥5% weight loss; 26% achieved ≥25% weight loss.

Comparative context: Semaglutide 2.4mg/week (STEP trials) produced ~15% mean weight loss. Tirzepatide 15mg/week (SURMOUNT trials) produced ~22.5%. Retatrutide 24mg/week produced 24.2% — with a safety profile that was acceptable in Phase 2.

GI Side Effects and Titration

The most common adverse event was nausea (40–60% during titration), vomiting (30%), and diarrhoea (25%). These are consistent with the GLP-1 class and are largely manageable with slow titration:

Weeks 1–4: 2mg/week
Weeks 5–8: 4mg/week
Weeks 9–12: 8mg/week
Maintenance: 8–12mg/week (most do not need 24mg)

Practical strategies: small, frequent meals; avoid high-fat foods initially; anti-emetics during titration if needed; stay hydrated.

The Lean Mass Problem and Solution

Approximately 10% of weight lost in Phase 2 was lean mass — similar to semaglutide. The glucagon component theoretically increases this risk, but hepatic fat oxidation effects appear to partially compensate. Still, lean mass preservation requires active intervention: resistance training (minimum 3x/week), high protein intake (1.6–2g/kg lean mass), and GH secretagogue support (ipamorelin + CJC-1295 before bed) — the Lean Mass Preservation Stack.